Inactive Instrument

OSPY MEDI CDI

Equities

OSP

AU000000OSP4

Osprey Medical, Inc. Provides Revenue Guidance for the Year 2020

February 24, 2020 at 04:39 pm

Osprey Medical, Inc. provided revenue guidance for the year 2020. In 2020, the company expects sales revenue to continue to grow as the number of hospitals and physicians using DyeVert and DyeVert Plus increases, with increased sales momentum from Osprey's GPO contracted hospital focus and the adoption of the new DyeVert Ez. The company expects revenue growth in Europe in 2020 as it is in advanced discussions with a party interested in European distribution rights.

Latest news about OSPY MEDI CDI

Osprey Medical Restructures Business; Aims to Reduce Credit	22-06-01	MT
Osprey Medical, Inc. Announces Board Changes	22-05-25	CI
Osprey Medical, Inc. Auditor Raises 'Going Concern' Doubt	22-04-19	CI
Osprey Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-27	CI
Transcript : Osprey Medical, Inc., Q4 2021 Earnings Call, Jan 31, 2022	22-01-30
Dyevert Announces Highlighted by Leading Experts for Reduction of Aki	21-10-27	CI
Osprey Medical : Fiscal Q1 Global Revenue Jumps 34%; Shares Rise 6%	21-10-19	MT
Transcript : Osprey Medical, Inc. - Special Call	21-10-19
Transcript : Osprey Medical, Inc. - Shareholder/Analyst Call	21-09-02
Osprey Medical, Inc. Announces Executive Appointments	21-08-16	CI
Osprey Medical, Inc. Announces Earnings Results for the Half Year Ended June 30, 2021	21-08-16	CI
Osprey Medical : Appoints New Board Member	21-08-12	MT
Osprey Medical, Inc. Appoints Martin Emerson to its Board of Directors	21-08-11	CI
Transcript : Osprey Medical, Inc., Q2 2021 Earnings Call, Jul 29, 2021	21-07-28
Osprey Medical : Expands DyeVert Technology to Canada	21-07-20	MT
Osprey Signs an Exclusive Distribution Agreement with GE Healthcare Canada Inc	21-07-19	CI
Osprey Medical, Inc. Announces Appointment of Steven Brandt as Director	21-06-30	CI
Transcript : Osprey Medical, Inc. - Shareholder/Analyst Call	21-05-10
Transcript : Osprey Medical, Inc., Q1 2021 Earnings Call, Apr 22, 2021	21-04-21
Osprey Medical, Inc. Reports Revenue Results for the First Quarter of 2021	21-04-21	CI
Osprey Medical : Pushes Sales Coverage in US; Shares Jump 5%	21-03-18	MT
Osprey Medical, Inc. Sigs Independent Sales Agency Agreements with St Patrick's Distributing Inc	21-03-17	CI
Osprey Medical : Expands US Sales Coverage With Three Sales Agreements	21-03-02	MT
Osprey Medical, Inc. Signs Independent Sales Agency Agreements with Access Medical Inc., Consolidated Medical Supplies Inc. and Drikot Medical Inc	21-03-01	CI
Transcript : Osprey Medical, Inc., Q4 2020 Earnings Call, Jan 28, 2021	21-01-27

Chart OSPY MEDI CDI

Duration

Period

More charts

Company Profile

Osprey Medical, Inc. is a commercial stage company, which is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company's products include AVERT, AVERT Plus, the DyeVert NG, DyeVert Plus, and DyeVert Plus EZ Systems. The AVERT Plus System reduces and monitors the amount of contrast dye used in commonly performed heart and peripheral vascular procedures. The DyeVert System is a self-adjusting product that reduces the amount of contrast dye used in commonly performed heart and peripheral procedures. DyeVert interfaces with syringe-manifold systems. These technologies are available with the United States Food and Drug Administration cleared indication for dye volume reduction. Its dye reduction and monitoring technologies are designed to help physicians minimize dye usage and reduce kidney damage associated with the use of contrast media for common cardiovascular procedures.

Sector

More about the company